Effects of levodopa on retina in Parkinson disease

European Journal of Ophthalmology

Volumn 24, Issue 1, 2013, Pages 114-119

  Sen, Aysu ^a   Tugcu, Betul ^a   Coskun, Cigdem ^a   Ekinci, Cansu ^a   Asik Nacaroglu, Senay ^a  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Levodopa; Optical coherence tomography; Parkinson disease; Retina

Indexed keywords

LEVODOPA;

ADULT; ANTERIOR EYE CHAMBER ANGLE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLAUCOMA; GONIOSCOPY; HOEHN AND YAHR SCALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA; RETINA FOVEA; RETINA GANGLION CELL; RETINAL NERVE FIBER LAYER THICKNESS; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL ACUITY; VISUAL FIELD DEFECT;

ADULT; AGED; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NERVE FIBERS; PARKINSON DISEASE; RETINA; RETINAL GANGLION CELLS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84889877298     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000338     Document Type: Article

References (26)

1. Fahn S, Przedborski S. Parkinsonism. Merritt's Textbook of Neurology, 11th ed. Philadelphia: Lippincott Williams & Wilkins;2005:828-846.
2. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992;42:887-890.
3. Bodis-Wollner I. Retinopathy in Parkinson disease. J Neural Transm 2009;116:1493-1501.
4. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990;31:2473-2475.
5. Djamgoz MB, Hankins MW, Hirano J, Archer SN. Neurobiol-ogy of retinal dopamine in relation to degenerative states of the tissue. Vision Res 1997;37:3509-3529.
6. Bodis-Wollner I. The visual system in Parkinson's disease. Res Publ Assoc Res Nerv Ment Dis 1990;67:297-316.
7. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res 2004;44: 2793-2797.
8. Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol 2009;127: 737-741.
9. Yavas GF, Yilmaz O, Küsbeci T, Oztürk F. The effect of levodopa and dopamine agonists on optic nerve head in Parkinson disease. Eur J Ophthalmol 2007;17:812-816.
10. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies [erratum 2005; 20: 645]. Mov Disord 2004;19:997-1005.
11. Olanow CW, Obeso JA. Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology 2011;77: 1416-1417.
12. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993;39:165-172.
13. Fahn S, Unified Parkinson's Disease Rating Scale Development Committee, Elton RL. Unified Parkinson's Disease Rating Scale: Recent Developments in Parkinson's Disease. New York: Raven; 1987:153-163.
14. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
15. Altintaş O, Işeri P, Ozkan B, Caǧlar Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. Doc Ophthalmol 2008;116:137-146.
16. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.
17. Parkkinen L, O'Sullivan SS, Kuoppamäki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 2011;77:1420-1426.
18. Whone AL, Watts RL, Stoessl AJ, et al. REAL-PET Study Group. Slower progression of Parkinson's disease with ro-pinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54:93-101.
19. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
20. Fahn S, Oakes D, Shoulson I, et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
21. Hendley ED, Snyder SH. Stereoselectivity of catecholamine uptake in noradrenergic and dopaminergic peripheral organs. Eur J Pharmacol 1972;19:56-66.
22. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990;31:2473-5.
23. Tsironi EE, Dastiridou A, Katsanos A, et al. Perimetric and retinal nerve fiber layer findings in patients with Parkinson's disease. BMC Ophthalmol 2012;12:54.
24. Albrecht P, Müller AK, Südmeyer M, et al. Optical coherence tomography in parkinsonian syndromes. PLoS One 2012;7:34891.
25. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord 2011;17:431-436.
26. Kirbas S, Turkyilmaz K, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in Parkinson disease. J Neuroophthal-mol 2013;33:62-65.